Firn

Firn M is a Russian biotechnology company founded in 1989, specializing in the development and production of recombinant interferon-based pharmaceuticals. The company is best known for its flagship product, Grippferon (recombinant interferon alpha-2b), which is a leading treatment for the prevention and therapy of influenza and acute respiratory viral infections (ARVI) in Russia and the CIS. Firn M's portfolio includes a variety of topical and systemic treatments for ophthalmology, allergy, gynecology, and dermatology, often combining interferon with other active ingredients like antihistamines or antivirals. Headquartered in Moscow, the company operates a GMP-compliant manufacturing facility and has expanded its research and development activities to include microbial platforms and probiotics, with a presence in Australia.